Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

SML2673

Sigma-Aldrich

Deferasirox

≥98% (HPLC)

Synonym(e):

4-[3,5-bis(2-Hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

10 MG
CHF 113.00
50 MG
CHF 455.00

CHF 113.00

Check Cart for Availability
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
10 MG
CHF 113.00
50 MG
CHF 455.00

About This Item

Empirische Formel (Hill-System):
C21H15N3O4
CAS-Nummer:
201530-41-8
Molekulargewicht:
373.36
MDL-Nummer:
MFCD09951804
UNSPSC-Code:
12352200
NACRES:
NA.77

CHF 113.00

Check Cart for Availability
Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

N2(N\C(=C4\C=CC=CC\4=O)\N\C\2=C3\C=CC=CC\3=O)c1ccc(cc1)C(=O)O

InChI

1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,22-23H,(H,27,28)/b19-15-,20-16+

InChIKey

FMSOAWSKCWYLBB-VBGLAJCLSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Deferasirox has been used as an iron chelator to test its effect on clofazimine mediated growth inhibition and rescue in Salmonella typhimurium.[1]

Biochem./physiol. Wirkung

Deferasirox belongs to the N-substituted bis-hydroxyphenyl-triazole family of tridentate iron chelators.[2]
Deferasirox is an orally available iron chelator used clinically for reduction of chronic iron overload in diseases such as β-thalassemia.
Orally available iron chelator

Piktogramme

Exclamation markEnvironment
GHS07,GHS09

Signalwort

Warning

H-Sätze

H302,H400

Gefahreneinstufungen

Acute Tox. 4 Oral - Aquatic Acute 1

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000245905
0000245905
0000198000
0000183094
0000154816

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Claudia Bollig et al.
The Cochrane database of systematic reviews, 8, CD007476-CD007476 (2017-08-16)
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.Both deferoxamine and deferiprone are effective;
Omid Reza Zekavat et al.
Journal of pediatric hematology/oncology, 43(1), e26-e28 (2020-09-15)
This study was performed on patients with transfusion-dependent beta-thalassemia (TDT) to investigate the effect of HFE gene mutations of iron overload in a large group of patients with TDT major and its relationship with heart and liver T2* magnetic resonance
Wataru Goto et al.
BMC cancer, 20(1), 1215-1215 (2020-12-12)
Iron is required for the proliferation of cancer cells, and its depletion suppresses tumor growth. Eribulin mesylate (eribulin), a non-taxane microtubule inhibitor, disrupts the tumor microenvironment via vascular remodeling and obstruction of the epithelial-mesenchymal transition (EMT). Herein, we investigated the
Aurelio Maggio et al.
The Lancet. Haematology, 7(6), e469-e478 (2020-05-30)
Transfusion-dependent haemoglobinopathies require lifelong iron chelation therapy with one of the three iron chelators (deferiprone, deferasirox, or deferoxamine). Deferasirox and deferiprone are the only two oral chelators used in adult patients with transfusion-dependent haemoglobinopathies. To our knowledge, there are no
Abbas Rahdar et al.
Life sciences, 270, 119146-119146 (2021-02-06)
Deferasirox (DFX) was formulated into oil-in-water microemulsions in the presence of pluronicto improve its oral bioavailability. The size of the DFX-loadedmicroemulsions system measured by dynamic light scattering (DLS) was about 9 nm. The anti-proliferative and anti-lipid peroxidation effects of DFX and
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.